Ohio Cancer Care Transformed by Zangmeister-OSU James Network Alliance

COLUMBUS, OH – May 21, 2026 – In a landmark move set to reshape cancer care delivery across central Ohio, Zangmeister Cancer Center has become an official affiliate of The Ohio State University’s prestigious James Cancer Network. The new partnership links Zangmeister, a community-based practice and partner of the American Oncology Network (AON), with one of the nation's leading academic medical institutions, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).

This affiliation creates a powerful synergy between accessible community oncology and cutting-edge academic medicine, promising to provide patients with a more seamless and comprehensive continuum of care. The collaboration is designed to enhance local access to world-class expertise, expand treatment options, and bring hundreds of clinical trials directly to the community, ultimately aiming to improve patient outcomes throughout the region.

A New Era of Patient Access in Central Ohio

The most immediate and significant impact of this affiliation will be felt by patients and their families. By integrating Zangmeister Cancer Center into The James Cancer Network, the partnership effectively eliminates many of the traditional barriers between community-based care and the highly specialized services of a major academic research center. Patients will now have enhanced, timely access to a vast array of advanced treatments and diagnostic tools without necessarily having to leave their local support systems.

At the forefront of these new opportunities is access to more than 500 clinical trials. The OSUCCC – James is one of only a handful of National Cancer Institute (NCI)-funded phase I/II clinical trial centers in the country, a designation that places it at the vanguard of cancer research. This means Zangmeister patients can now be more easily connected to innovative therapies that are often years away from widespread availability. This expanded access is a critical lifeline for patients with complex or hard-to-treat cancers.

Beyond clinical trials, the affiliation opens pathways to some of the most advanced cancer therapies available today. These include cellular therapies like CAR T-cell therapy and tumor-infiltrating lymphocyte (TIL) therapy, as well as highly targeted radiation treatments such as proton therapy, which is offered at the OSUCCC – James’ state-of-the-art center that opened in late 2023. These sophisticated treatments, which require immense institutional expertise and infrastructure, are now part of the extended toolkit available to Zangmeister’s care teams.

“We are excited to offer our patients expanded options for cancer treatment,” said Jeanna Knoble, MD, medical oncologist and managing partner at Zangmeister Cancer Center. “Being an affiliate of The James Cancer Network allows us to extend specialized treatment pathways when needed, including access to clinical trials, CAR T-cell therapy, stem cell transplant evaluation and other highly specialized services. It reinforces our commitment to delivering high-quality care rooted in the community with access to academic excellence.”

The Strategic Synergy Reshaping Ohio's Oncology Landscape

This partnership represents more than just a clinical collaboration; it is a strategic maneuver that reflects the evolving landscape of healthcare in the United States. It combines the strengths of two distinct but complementary models: the community-based efficiency and patient-centric focus of AON and Zangmeister, and the research-driven, subspecialized power of an NCI-designated Comprehensive Cancer Center like the OSUCCC – James.

For Ohio State, the affiliation extends the reach of its academic mission and clinical trials into the community, broadening its impact and patient base. For Zangmeister and its parent network AON, it provides an invaluable link to academic prestige and cutting-edge resources, enhancing its competitive position and elevating the level of care it can offer.

“Stronger collaboration between community oncology and academic medicine benefits the entire community,” said W. Kimryn Rathmell, MD, PhD, director of The Ohio State University Comprehensive Cancer Center. “This affiliation expands access to clinical trials and the most advanced therapies. By working together, we ensure patients receive timely, high-quality cancer care.”

This model creates a formidable presence in the central Ohio healthcare market, potentially prompting other regional providers to re-evaluate their own networks and partnerships. By creating a direct, formalized pathway between community and academic care, the Zangmeister-James affiliation sets a new standard for integrated oncology services in the region.

Steven Swart, executive vice president of practice operations at American Oncology Network, underscored the strategic vision. “This affiliation reflects our commitment to expanding access to innovative, evidence-based cancer care and ensuring patients across central Ohio benefit from both community-based care and academic expertise,” he stated, highlighting AON's role in fostering such high-impact partnerships.

A Blueprint for the Future of Integrated Cancer Care

Industry experts view the Zangmeister-James affiliation as a prime example of a forward-thinking healthcare model that could serve as a blueprint for oncology care nationwide. It moves away from the historically siloed approach—where patients were often forced to choose between the convenience of a local clinic and the resources of a distant academic hospital—and toward a fluid, hybrid system.

This integrated model is designed to create a seamless patient journey. A person could be diagnosed and begin standard treatment at their local Zangmeister facility, and if their condition requires a more specialized approach, their care team can coordinate directly with experts at the OSUCCC – James. Shared medical records and collaborative case reviews are expected to ensure that the patient’s local care team remains an active participant, providing continuity and support even as treatment becomes more specialized. This approach ensures that patients benefit from the best of both worlds: academic innovation delivered with the personal touch of community-based care.

The partnership's scope extends beyond direct clinical services. The agreement includes plans for coordinated community outreach and expanded medical education opportunities for physicians and care teams. This commitment will help elevate the overall standard of cancer care across the region by disseminating the latest knowledge and best practices, further strengthening the healthcare ecosystem in central Ohio and beyond.